Supplementary Table 1 from A Call for Innovative Translational and Clinical Research to Address China’s Unique Cancer Landscape

Zhang, Chaoqi; Wu, Peng; Li, Dongyu; Gu, Xuanyu; Lin, Chuqi; Zhou, Junhan; Shang, Dexin; Liu, Jingjing; Ma, Ruijie; Zhao, Bohui; Sun, Nan; He, Jie

doi:10.1158/2159-8290.27435745

Supplementary Table 1 from A Call for Innovative Translational and Clinical Research to Address China’s Unique Cancer Landscape

https://doi.org/10.1158/2159-8290.27435745

journal contribution

posted on 2024-11-01, 07:41 authored by Chaoqi Zhang, Peng Wu, Dongyu Li, Xuanyu Gu, Chuqi Lin, Junhan Zhou, Dexin Shang, Jingjing Liu, Ruijie Ma, Bohui Zhao, Nan Sun, Jie He

<p>Supplementary Table 1. The number of Investigational New Drug (IND) and New Drug Application (NDA) applications retrieved from the Annual Drug Evaluation Report by the Center for Drug Evaluation (CDE) from 2018-2023.</p>

History

Related Materials

1.
DOI - Is supplement to A Call for Innovative Translational and Clinical Research to Address China’s Unique Cancer Landscape

ARTICLE ABSTRACT

The Chinese government has, in recent decades, implemented various administrative laws and regulatory policies to expedite cancer therapeutic development, boosting research and development pipelines for domestic pharmaceutical companies and clinical trials; however, China faces unique challenges given the high prevalence of certain cancer types and distinct disease burdens, some of which are frequently overlooked by international pharmaceutical companies. Given the substantial unmet need for China-specific cancer care, it is crucial to promote the development of innovative pharmaceutical and clinical research in China, with a particular emphasis on addressing tumors most prevalent in its population.

Supplementary Table 1 from A Call for Innovative Translational and Clinical Research to Address China’s Unique Cancer Landscape

History

Related Materials

ARTICLE ABSTRACT

Usage metrics

Categories

Keywords

Licence

Exports